Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male or female of ages 18 to 50 inclusive~2. Body weight \> 50 kg (110 lb.) and body mass index between 18 and 32 kg/m2 inclusive~3. Medically healthy with clinically insignificant findings based on medical history, 12-lead ECG, and physical examination~4. Negative urine pregnancy test in women of childbearing potential~Exclusion Criteria:~1. Previous exposure to pegfilgrastim or filgrastim, or known allergy to PEG (polyethylene glycol)~2. Chemistry and hematology values outside protocol specified range~3. Current or previous cancer, diabetes, or any clinically significant cardiovascular, metabolic, renal, hepatic, gastrointestinal, hematologic, respiratory, dermatological, neurological, psychiatric, or other disorder~4. History of chronic or acute respiratory illness within the past 4 weeks~5. Positive urine drug or alcohol screen or unwillingness to abstain from alcohol or recreational drugs for the duration of study participation~6. No prescription or nonprescription drugs during the study~7. Participation in an investigational clinical study within 30 days prior to screening~8. Known or suspected allergic reaction to latex

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- CHS-1701/Neulasta (Type: EXPERIMENTAL): CHS-1701 followed by Neulasta (crossover)
- Neulasta/CHS-1701 (Type: EXPERIMENTAL): Neulasta followed by CHS-1701 (crossover)

Based on this trial design, predict the completion outcome and termination type (if applicable).